Reply to Dorgham et al., “Considering Personalized Interferon Beta Therapy for COVID-19”

Benzer Materyaller

• Considering Personalized Interferon Beta Therapy for COVID-19
  Yazar:: Dorgham, Karim, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19
  Yazar:: Davoudi-Monfared, Effat, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• The threat of carbapenem-resistant gram-negative bacteria in a Middle East region
  Yazar:: Davoudi-Monfared, Effat, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial
  Yazar:: Rahmani, Hamid, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Authors’ Reply to Vrachatis et al. “Pharmaco-Immunomodulatory Therapy in COVID-19”
  Yazar:: Rizk, John G., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)